)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Shanghai Henlius Biotech
Shanghai Henlius Biotech (2696) investor relations material
Shanghai Henlius Biotech H1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2026 earnings summary21 Aug, 2026
Executive summary
2026 H1 revenue reached RMB 3.59B, up 27.3% year-over-year, driven by drug sales, R&D services, and licensing income.
Net profit for 2026 H1 was RMB 430.4M, a 10.3% increase year-over-year; non-IFRS profit at RMB 572.3M and EBITDA at RMB 904.1M.
Over 1,100,000 patients benefited globally; 10 products (41 indications) approved in 60+ countries/regions.
Major product launches and regulatory milestones achieved in China, US, EU, Korea, and other regions, including HANSIZHUANG and HLX11.
Financial highlights
Gross profit for 2026 H1 was RMB 2.77B, up 25.9% year-over-year.
Ex-China/overseas product revenue surged 159.4% year-over-year to RMB 110M; overseas profit grew over fourfold.
R&D expenditure increased 45.8% year-over-year to RMB 1.45B, supporting innovation and pipeline expansion.
Cash and bank balances at RMB 818.4M as of June 30, 2026; operating cash inflow was RMB 559M.
BD and other revenue grew 167.3% year-over-year to RMB 702M.
Outlook and guidance
More than 10 new products expected to launch globally in the next few years, driven by a robust biosimilar and innovative pipeline.
Plans to submit BLAs for HANSIZHUANG and HANBEITAI in the US and EU in 2026.
Continued focus on international expansion, with strategic partnerships and in-licensing to maximize commercial synergies.
Multiple IND applications and clinical milestones expected for innovative assets in H2 2026 and 2027.
Focus on leveraging AI in R&D and deepening global market presence.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Shanghai Henlius Biotech
- Revenue rose 67.8% and profitability returned, led by biosimilar and serplulimab growth.2696
H2 2023 - Strong clinical pipeline, global expansion, and key regulatory milestones drive future growth.269644th Annual J.P. Morgan Healthcare Conference
- Revenue up 16.5% to RMB6.67B, net profit at RMB827M, global expansion and R&D drive growth.2696H2 2025
- Revenue up, net loss widened on R&D; HLX02 approved in EU/China, capacity expanded.2696H1 2020
- Revenue and profit rose 2.7% YoY, driven by global expansion and new product approvals.2696H1 2025
- Net profit surged 61% to RMB386.3M on strong sales, global expansion, and pipeline progress.2696H1 2024
- Net profit rose 50% to RMB 820M on 6.1% revenue growth and global expansion.2696H2 2024
Next Shanghai Henlius Biotech earnings date
H2 202619 Mar, 2027
Shanghai Henlius Biotech
Next Shanghai Henlius Biotech earnings date
H2 202619 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Shanghai Henlius Biotech Inc is a biopharmaceutical company focused on the research, development, manufacturing, and commercialization of biologic drugs, particularly biosimilars and monoclonal antibody therapies. The company’s product portfolio addresses a range of therapeutic areas, including oncology, autoimmune diseases, and infectious diseases. Henlius operates advanced manufacturing facilities and research centers, employing innovative biotechnology to support its drug development pipeline and expand access to biologic treatments. The company is headquartered in Shanghai, China, and its shares are listed on the HKEX.